The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Jul. 16, 2018
Applicant:

University of Tenessee Research Foundation, Knoxville, TN (US);

Inventors:

Jonathan S Wall, Knoxville, TN (US);

Stephen J Kennel, Kingston, TN (US);

James S Foster, Knoxville, TN (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61P 27/02 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 14/47 (2006.01); A61K 47/66 (2017.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39583 (2013.01); A61K 38/1716 (2013.01); A61K 39/395 (2013.01); A61K 47/66 (2017.08); A61K 47/6891 (2017.08); A61K 51/10 (2013.01); C07K 14/4711 (2013.01); C07K 16/18 (2013.01); G01N 33/53 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/34 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); G01N 2333/4709 (2013.01);
Abstract

Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.


Find Patent Forward Citations

Loading…